While the efficacy of SMO inhibitors in BCC and medulloblastoma is satisfactory, clinical trials in other solid cancers including colorectal, pancreatic, or lung cancer were disappointing [212,213,214]. Here, SMO is linked to skin basal cell carcinoma.